Concourse Financial Group Securities, Inc. Novavax Inc Transaction History

Concourse Financial Group Securities, Inc.

  • $1.52 Billion
  • Q1 2024
Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 30, 2024
BUY
$3.76 - $6.02 $0 - $0
0 New
0 $0
Q4 2023

Feb 07, 2024
BUY
$4.8 - $7.67 $0 - $0
0 New
0 $0
Q3 2023

Oct 30, 2023
BUY
$6.81 - $9.74 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023
BUY
$6.81 - $9.74 $0 - $0
0 New
0 $0
Q2 2023

Aug 10, 2023
BUY
$6.67 - $9.52 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023
BUY
$5.76 - $12.48 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023
BUY
$8.86 - $25.04 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$18.2 - $76.12 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$36.28 - $75.29 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
SELL
$69.73 - $142.9 $1,743 - $3,572
-25 Closed
0 $0
Q3 2021

Nov 09, 2021
BUY
$177.8 - $270.58 $4,445 - $6,764
25 New
25 $5,000
Q2 2021

Aug 13, 2021
SELL
$121.0 - $257.67 $1,210 - $2,576
-10 Closed
0 $0
Q1 2021

May 13, 2021
BUY
$112.98 - $319.93 $1,129 - $3,199
10 New
10 $2,000
Q4 2020

Feb 02, 2021
BUY
$78.74 - $139.5 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020
SELL
$79.44 - $178.51 $11,916 - $26,776
-150 Closed
0 $0
Q2 2020

Aug 13, 2020
BUY
$13.86 - $83.61 $2,079 - $12,541
150 New
150 $13,000
Q1 2020

May 13, 2020
BUY
$3.93 - $16.0 $0 - $0
0 New
0 $0
Q4 2019

Feb 14, 2020
BUY
$3.69 - $5.22 $0 - $0
0 New
0 $0
Q3 2019

Nov 13, 2019
BUY
$4.02 - $7.84 $0 - $0
0 New
0 $0
Q2 2019

Aug 13, 2019
BUY
$4.93 - $12.2 $0 - $0
0 New
0 $0

Others Institutions Holding NVAX

# of Institutions
242
Shares Held
76.1M
Call Options Held
5.06M
Put Options Held
7.19M
View Full List

About NOVAVAX INC

NVAX Quotes by TradingView
  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $1.01B
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email